Production (Stage)
BioXcel Therapeutics, Inc.
BTAI
$1.39
$0.021.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.25M | -10.86M | -13.65M | -8.30M | -26.79M |
| Total Depreciation and Amortization | 76.00K | 77.00K | 77.00K | 77.00K | 78.00K |
| Total Amortization of Deferred Charges | 350.00K | 222.00K | 106.00K | 96.00K | 43.00K |
| Total Other Non-Cash Items | -3.63M | -7.54M | -1.55M | -9.63M | 4.69M |
| Change in Net Operating Assets | -1.58M | 3.29M | -1.32M | -5.42M | 4.27M |
| Cash from Operations | -12.04M | -14.81M | -16.34M | -23.17M | -17.71M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -2.50M | -- | -- | -- |
| Issuance of Common Stock | 14.01M | 7.00M | 468.00K | 5.48M | 26.74M |
| Repurchase of Common Stock | -1.00K | -46.00K | 0.00 | -8.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -803.00K | -179.00K | -14.00K | -164.00K | -117.00K |
| Cash from Financing | 13.20M | 4.28M | 454.00K | 5.30M | 26.63M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.16M | -10.53M | -15.88M | -17.87M | 8.92M |